Hologic (HOLX)
(Delayed Data from NSDQ)
$80.76 USD
+0.38 (0.47%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $80.75 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.76 USD
+0.38 (0.47%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $80.75 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Crude Bucks Choppy Trend - Dave's Daily Dive
by David Bartosiak
Crude bucked the choppy trend in markets today as equities sloshed back-and-forth most of the day
New Strong Buy Stocks for April 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Hologic Completes Cynosure Buyout, Boosts Core Business
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the completion of it earlier declared acquisition of marketer of aesthetic treatment systems, Cynosure, Inc.
Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal
by Zacks Equity Research
Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).
Hologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance
by Zacks Equity Research
Hologic Inc. (HOLX) reported first-quarter fiscal 2017 adjusted earnings per share (EPS) of 52 cents, up 13% year over year.
Medical Instrument Stocks' Earnings on Feb 1: EW, HOLX, BABY
by Zacks Equity Research
Already more than one-third of the S&P 500 members (170 companies making up for 19.2% of the total market cap) have reported their Oct--Dec 2016 quarter's earnings results.
4 Good Reasons to Focus on the USA: Global Week Ahead
by John Blank
In the Global Week Ahead, the bulk of any trader???s time should focus on the good ol' USA. Why do we think that? There are four old-fashioned reasons.
Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.
Quality Systems (QSII) Beats on Earnings & Revenues in Q3
by Zacks Equity Research
Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.
Varian Medical (VAR) Misses on Q1 Earnings and Revenues
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.
McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal
by Zacks Equity Research
McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.
Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance
by Zacks Equity Research
Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.
Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) posted adjusted earnings of $5.30 per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate by four cents.
Is a Surprise in Store for Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Hologic Inc. (HOLX) is slated to report first-quarter fiscal 2017 financial results on Feb 1, after the closing bell.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic
3 Medical Device Stocks Likely to Beat Earnings Estimates
by Zacks Equity Research
The likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.
Hologic (HOLX) to Divest Blood Screening Business to Grifols
by Zacks Equity Research
Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.
Hologic Hits 52-Week High on Q4 Earnings & Solid Prospects
by Zacks Equity Research
Share price of Bedford, MA-based Hologic Inc. (HOLX) reached a new 52-week high of $41.01 on Dec 14, finally closing a tad lower at $40.79.
Whole Foods (WFM) Will No Longer be Part of Nasdaq-100
by Zacks Equity Research
As a result of the annual re-ranking of the NASDAQ-100 index, Whole Foods (WFM) will cease to be a part of the same.
Bed Bath and Beyond (BBBY) Loses its Place in Nasdaq-100
by Zacks Equity Research
The NASDAQ-100 Index as part of its annual re-ranking process has decided to remove Bed, Bath & Beyond Inc. (BBBY).
4 Medical Instrument Stocks to Bet on This Earnings Season
by Zacks Equity Research
The medical instrument sector holds a lot of promise at this moment.
Top 3 MedTech Stocks Poised to Gain this Earnings Season
by Zacks Equity Research
A bipartisan group of ten senators signed on a bill to repeal the 2.3% federal excise tax on medical device makers.